Samantha Xavier, MD
Ophthalmology · Ocoee, FLNPI 1316240690
Payments from drug & device makers
Across 175 payments — averaging $2272.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$188K
- Ocular Therapeutix, Inc.$90K
- Aerie Pharmaceuticals, Inc.$80K
- Regeneron$25K
- Astellas Pharma Global Development$8K
- Alcon$1K
- plus $5K from 21 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 19 | $188,372 |
| Ocular Therapeutix, Inc. | 10 | $89,861 |
| Aerie Pharmaceuticals, Inc. | 15 | $80,232 |
| Regeneron | 5 | $25,291 |
| Astellas Pharma Global Development | 1 | $7,793 |
| Alcon | 23 | $1,435 |
| Bausch & Lomb Americas Inc. | 8 | $815 |
| Regeneron Healthcare Solutions, Inc. | 19 | $635 |
| Glaukos Corporation | 4 | $522 |
| Apellis Pharmaceuticals, Inc. | 19 | $456 |
| AbbVie(2 entities) | 6 | $319 |
| Alimera Sciences, Inc. | 6 | $296 |
| Astellas Pharma US Inc | 11 | $221 |
| Harrow Eye, LLC | 7 | $218 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $216 |
| Rxsight Inc | 2 | $215 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $203 |
| Tarsus Pharmaceuticals, Inc. | 2 | $144 |
| Dompe US, Inc. | 1 | $93 |
| Mallinckrodt Hospital Products Inc. | 1 | $93 |
| Silk Road Medical, Inc. | 1 | $92 |
| Genentech USA, Inc. | 4 | $79 |
| Rayner Intraocular Lenses Limited | 1 | $42 |
| ANI Pharmaceuticals, Inc. | 2 | $40 |
| Oyster Point Pharma, Inc. | 2 | $30 |
| Coherus Oncology, Inc. | 1 | $21 |
| Notal Vision, Inc. | 1 | $17 |
How this compares
$397,750 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Ocoee
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
- Benjamin ThomasJacksonville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.